Navigation Links
Moffitt cancer center researchers find novel predictor for MDS progression risk
Date:9/12/2012

Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) to acute myeloid leukemia. The finding could improve prognostication for patients with MDS and better inform therapeutic decision making.

The study published in the August issue of The Journal of Immunology.

Awareness of the condition increased earlier this year when ABC's "Good Morning America" co-anchor Robin Roberts announced that she is battling MDS. Formerly known as pre-leukemia, MDS is a collection of blood disorders. One in three patients with MDS develops bone marrow failure and progresses to acute myelogenous leukemia within the first few years after diagnosis.

MDS involves the ineffective production of blood cells in bone marrow and often leaves patients anemic and in need of frequent blood transfusions.

The disease may develop as the result of chemotherapy or radiation for cancer treatment or can be related to bone marrow failure resulting from frequent transfusions and subsequent iron overload. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, a patient's organs can become overloaded with iron, leading to heart failure, liver injury, susceptibility to infection and other complications. Bone marrow transplantation may be necessary.

Seeking to understand more about the development of MDS, Moffitt researchers and their colleagues investigated aspects of the immune system, particularly the role of regulatory T cells, also known as Tregs. Tregs, said the researchers, are well-defined players in tumor immune invasion in solid tumors, but little is known about the role Tregs play in pre-malignant human diseases.

"We investigated a Treg subset called 'effector memory Tregs,' " said study senior author Pearlie K. Epling-Burnette, Pharm.D., Ph.D., senior member of Moffitt's Immunology Department. "We found that changes in the physical characteristics, or phenotypes, of Tregs in MDS suggest that they may be recently activated in a manner similar to effector memory T cells. By looking at a patient's effector memory Treg cells, we were able to identify patients at higher risk for MDS progression."

An increase in effector memory Tregs likely reflects active immune suppression and may represent the earliest biomarker indicating conversion to an immunosuppressive microenvironment, the researchers said.

The team concluded that the changes to effector memory Treg phenotype may also be a useful tool for identifying MDS patients who may respond to specific classes of drugs. This would make inclusion of a patient's Treg status into prognostic and treatment models potentially valuable for informing therapy decisions for patients with MDS.

"Our study sheds light on a unique aspect of T cells and immunity in a pre-malignant model of disease and specifically implicates the importance of changes to effector memory Tregs," concluded Epling-Burnette and her co-authors. "Our findings specifically implicate effector Treg expansion in disease progression in MDS."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers say race affect likelihood of finding suitable stem cell donor
2. Moffitt Cancer Center researchers study childhood melanoma characteristics
3. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
4. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
5. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
6. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
7. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
8. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
9. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
10. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
11. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the India ... need of skilled pediatric dentistry in Rock Hill, SC, without a referral. ... treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. , ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, LLC, ... experience and operational excellence in oncology clinical trials, proudly announces today that it ... of non-small cell lung cancer and small cell lung cancer. , Throughout this ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... financial planning, and related services to communities across eastern Texas, is announcing a ... of providing meals to hungry children and adults. , Consistently a top-rated ...
(Date:3/22/2017)... NC (PRWEB) , ... March 22, 2017 , ... Chris ... assistance to families and business professionals throughout the coastal plains region, is initiating a ... to overcome cancer. , Dillyn was first diagnosed with leukemia on a Friday evening ...
(Date:3/22/2017)... CANADA (PRWEB) , ... March 22, 2017 , ... HumanHaus ... today, the Sweep&Stand. The conventional broom was great when it was invented, but ... They are the working parents, the social young couple, the empty nesters and retired ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 TFS is pleased ... Mr. Ed Tumaian , two global executive positions in Medical ... joining the Operational Leadership Team and will report to Dr. ... ... to TFS with 10 years of medical and scientific expertise gained ...
(Date:3/22/2017)... N.Y. , March 22, 2017  As the ... Leukemia & Lymphoma Society (LLS) has played a role ... patients, some of which are even helping patients with ... due to LLS,s significant investment in cutting-edge research – ... milestone continues to grow with the record-breaking sum of ...
(Date:3/22/2017)... NetworkNewsWire Editorial Coverage  ... Deciphering marijuana policy under the Trump ... officials. Federal laws are at odds with a number of ... and businesses like SinglePoint, Inc. (OTC: SING) ( SING Profile ... (OTC: MJNA), Cannabis Science, Inc. (OTC: CBIS) and ChineseInvestors.com, Inc. ...
Breaking Medicine Technology: